Biovica International
19.11.2021 16:17:02 CET | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / November 19, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)
Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum®TKa budget impact model. All studies focused on the role of DiviTum®TKa in monitoring treatment in women with metastatic breast cancer.
Biovica and Carrick Therapeutics have collaborated on generating TK activity (TKa) data in the phase 1/2A study of samuraciclib (NCT033638939), a first-in-class, oral, selective inhibitor of CDK7 that recently received fast track designation from the US Food and Drug Administration (FDA). The study demonstrates the potential association of TKa levels with treatment effect for this next generation CDK inhibitor.
P1-18-10 A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
DiviTum®TKa results from the clinical study PROMISE (NCT03281902) conducted at the Mayo Clinic show the association of TKa with progression free survival. The study results are a continuation of the results presented on SABCS 2020. Since then, the study has continued and samples from almost twice as many patients have been tested for TKa, with the new results confirming the initial analysis and earlier DiviTum®TKa results - i.e., the usage of DiviTum®TKa as a valuable tool in the evaluation of treatment effect in metastatic breast cancer.
P5-13-22 Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)
Additional results of the healthcare DiviTum®TKa Budget Impact Model show the potential for DiviTum®TKa to substantially reduce the number of CT scans and bone scans used in monitoring women with metastatic breast cancer. As these scans are both costly and a burden on patients, this reinforces the potential benefit of DiviTum®TKa to healthcare systems and to patients. Additionally, the test may enable early identification when a treatment is not effective and therefore enable overall savings of three times the added spend on the DiviTum®TKa test.
P3-03-05 The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
"The data on DiviTum®TKa being presented at SABCS strengthens the scientific and economic foundation for the role of the test in the care of breast cancer patients. We are very pleased with these results," said Anders Rylander, CEO of Biovica.
The San Antonio Breast Cancer Symposium, SABCS, runs December 7-10, 2021.
Contact:
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.
Attachments
Biovica's DiviTum®TKa in three studies at SABCS 2021
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/673809/Biovicas-DiviTumRTKa-in-Three-Studies-at-SABCS-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IAVI Awarded $36 Million From BARDA for Bundibugyo Virus Vaccine Development28.10.2026 16:50:00 CET | Press release
NEW YORK, NY, SINGAPORE, SG INCHEON, SOUTH KOREA, AND DESSAU-ROSSLAU, DE / ACCESS Newswire / October 28, 2026 / Today IAVI, a global nonprofit biomedical research organization, together with partners Hilleman Laboratories, SK bioscience, and IDT Biologika announced that IAVI has been awarded US $36 million of a contract valued up to US $99 million from the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to advance development, manufacturing, and clinical evaluation of its one-dose vaccine candidate against Bundibugyo virus (BDBV), the cause of the ongoing Ebola epidemic in the Democratic Republic of the Congo (DRC). The award supports manufacturing of vaccine doses for clinical evaluation and outbreak response, clinical and regulatory activities including a Phase 1 trial, and options for expanded manufacturing to support future preparedness needs, as
GA-ASI and Saab Perform Advanced AEW Flight Testing on Uncrewed MQ-9B28.10.2026 16:00:00 CET | Press release
SAN DIEGO, CA / ACCESS Newswire / October 28, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has partnered with Saab to perform advanced flight testing of an Airborne Early Warning (AEW) system on an Uncrewed Aircraft System (UAS). The flight testing was conducted over the past few months using a GA-ASI-produced MQ-9B carrying a Saab LoyalEye radar operating from GA-ASI's Desert Horizon flight operations facility in Southern California. The flight test demonstrated simultaneous tracking of several airborne and maritime targets at long ranges. The airborne targets tracked included multiple instrumented red fighter jets and several commercial aircraft. MQ-9B is GA-ASI's flagship UAS, offering unmatched endurance, type certification and all-weather performance. GA-ASI is discussing unmanned AEW capabilities on MQ-9B with several customers. "This has been one of the most highly anticipated flight tests we have performed," said GA-ASI President David R. Alexander. "The level of
Juno Corp. Closes $25 Million Non-Brokered Private Placement28.10.2026 12:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / October 28, 2026 / Juno Corp. ("Juno" or the "Company"), the largest mineral claim holder and most active explorer in Ontario's Ring of Fire, is pleased to announce that it has completed a non-brokered private placement (the "Offering") for aggregate gross proceeds of $25,290,609. Pursuant to the Offering, the Company issued an aggregate of (i) 165,750 common shares of Juno ("HD Juno Shares"), on a non-flow-through basis at a price of $4.00 per HD Juno Share, (ii) 404,890 common shares of Juno that qualify as "flow-through shares" as defined in subsection 66(15) of the Income Tax Act (Canada) (the "Tax Act") (the "FT Juno Shares"), at a price of $4.50 per FT Juno Share, and (iii) 4,131,450 common shares of Juno, which qualify as "flow-through shares" as defined in subsection 66(15) of the Tax Act (the "Premium FT Juno Shares", and together with the HD Juno Shares and the FT Juno Shares, the "Juno Securities"), at a price of $5.52 per Premium FT Juno Shar
DistillerSR Launches Smart Chat, an AI Chat Interface Built Into Its Evidence Platform27.10.2026 15:55:00 CET | Press release
OTTAWA, ON / ACCESS Newswire / October 27, 2026 / DistillerSR® Inc., the pioneer and market leader in AI-enabled literature review automation and evidence management, today announced the launch of Smart Chat. Smart Chat brings DistillerSR's Agentic AI capabilities in-platform. Since September 2025, DistillerSR Agentic AI has eliminated evidence silos at customer organizations by connecting Large Language Models to a repository of expertly validated literature evidence. Smart Chat now makes that same capability available natively within DistillerSR's secure platform. "While researchers recognize the power of generative AI, many life sciences organizations cannot risk connecting external LLMs to their sensitive research data," said Peter O'Blenis, CEO of DistillerSR. "Smart Chat removes that barrier. It is built directly into the platform teams already use, works exclusively with their own DistillerSR projects, and is included with every version of DistillerSR." Smart Chat works only wit
PuK Gaming Launches First Officially Licensed Fortnite Mobile Accessories Range27.10.2026 14:15:00 CET | Press release
LONDON, UK / ACCESS Newswire / October 27, 2026 / PuK Gaming LTD, the UK-based designer of premium mobile gaming accessories, today launched Drop 1 of its officially licensed Fortnite range, in a deal facilitated by Epic Games' licensing agency IMG Licensing. The five-product range offers console-grade control to how millions play Fortnite: on a phone. The PuK Thumbstick, PuK Triggers, PuK Link Cable and PuK Thumb Sleeves attach in seconds, no battery charge or pairing required; the whole ecosystem fits in your pocket. The Hot Drop Bundle includes three of the four products, plus a collector tin and zip case. Every Drop 1 product includes a code for a bonus in-game item, with the Thumbstick granting the Stage Dive Glider and the Hot Drop Bundle granting the Battle Call Emote. "Fortnite defines competitive play for mobile gamers," said Scotty Tidwell, CEO of PuK Gaming. "Drop 1 gives Fortnite players more ways to play on mobile with console-grade low-latency control and precision." PuK
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom